Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

System1 reiterates rejection of Brave Bison's revised offer

(Sharecast News) - System1 reiterated its unanimous rejection of Brave Bison's revised cash-and-share proposal on Friday, saying feedback from major shareholders supported the board's view that the offer materially undervalued the company. The possible offer comprises 68p in cash and 2.7553 new Brave Bison shares for each System1 share, valuing the business at 317p per share based on Brave Bison's 10 July closing price and representing a premium of about 4% to System1's price on the same date.

System1 said the proposal offered no meaningful control premium and failed to reflect its stronger trading outlook following record second-half revenue and new business performance.

Using closing prices on 16 July, the terms represented a 4.9% discount to System1's market value, and the board advised shareholders to take no action while noting there was no certainty that a formal offer would be made.

At 0828 BST, shares in System1 Group were up 1.54% at 330p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

Share this article

Related Sharecast Articles

Oakley Capital Investments acquires enterprise AI data platform Graphwise
(Sharecast News) - London-listed Oakley Capital Investments announced on Wednesday that one of its funds has acquired knowledge graph and semantic data technology firm Graphwise.
Target hikes FY outlook after strong Q2 and tariff uplift
(Sharecast News) - Target posted another strong set of quarterly numbers on Wednesday, with tariff refunds giving earnings an additional lift and prompting the retailer to raise its full‑year guidance as its turnaround continued to take hold.
Thursday preview: Walmart, Hays, JD Sports results due
(Sharecast News) - On Thursday, UK corporate releases will include full-year results from recruiter Hays and a trading statement from sportswear retailer JD Sports.
Moderna, Merck surge on positive trial results for melanoma vaccine
(Sharecast News) - Merck and Moderna surged on Wednesday after the pharmaceutical companies said a personalised mRNA melanoma vaccine they are jointly developing showed positive results in a first-ever late-stage trial.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.